A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma

To be able to join this study, your doctor must first confirm that you have multiple myeloma. This diagnosis needs to meet specific international guidelines. Your cancer also needs to be measurable, meaning doctors can track its progress with tests, either through a central lab or your local lab depending on which part of the study you might join. You should also generally be well enough to take part in a study, meaning you can carry out most of your normal daily activities without too much difficulty.

There are also some important things that might mean you can't join. For example, if you've recently had certain types of immunotherapy treatment (like CAR-T or T-cell redirection therapy), you might not be eligible, though the exact timing varies depending on which group in the study you might be in. Any side effects from your previous cancer treatments should have mostly cleared up – generally back to how they were before, or only very mild. You also shouldn't have taken a high dose of steroid medicines in the two weeks before starting the study drug, unless it was for a one-off treatment. Serious health events like a stroke or seizure within the last six months would also mean you couldn't participate in this study.

Also, if you are a woman who could become pregnant, you would need to have a negative pregnancy test before starting the study medicine. Everyone joining the study must be willing and able to follow all the study's rules and treatment plan.

If you decide to take part in this study, you will be given the study medicine, talquetamab. The specific details of how often and for how long you receive the treatment will be carefully explained to you by the study team. You will have regular visits to the clinic so the doctors can monitor your health, check how you're responding to the treatment, and look for any side effects. These visits will involve various assessments, such as blood tests, physical examinations, and potentially other scans or tests to measure your multiple myeloma. Your doctors will explain all scheduled appointments and tests to you.

The total duration of your participation in the study will depend on how you respond to the treatment and the study plan. Even after you stop receiving the study medicine, you will likely have some follow-up visits or contact to ensure your health is still being monitored. The study team will make sure you understand the full schedule and commitment involved before you make any decisions.